11:32 AM EDT, 04/30/2025 (MT Newswires) -- Bristol-Myers Squibb's ( BMY ) new under-the-skin injection version of cancer drug Opdivo has received approval from the UK's Medicines and Healthcare products Regulatory Agency, the regulator said Wednesday.

The agency said the new version of the drug offers a "quicker administration option for eligible patients."

Common cancers like lung, bowel, kidney, bladder, oesophageal, skin, as well as head and neck cancers can be treated with Opdivo, the regulator said.

Bristol-Myers Squibb ( BMY ) shares were up over 1% in recent trading.

Price: 49.80, Change: +0.58, Percent Change: +1.18